Hanane ABBOU

Dr. Hanane ABBOU

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IZIlham Zarguan
Ilham Zarguan
HAHanane ABBOU
Hanane ABBOU
RZRazana Zegrari
Razana Zegrari
RFRihab FESTALI
Rihab FESTALI
DBDevan Buchanan
Devan Buchanan
LBLamiae Belayachi Belayachi
Lamiae Belayachi Belayachi
Marrubium vulgare L. is a medicinal plant widely used in traditional medicine, with emerging evidence of anticancer potential. This study investigated its bioactive compounds as inhibitors of Heat Shock Protein 90 alpha (Hsp90α), a molecular chaperone essential for oncogenic protein stability. Organic and aqueous extracts were profiled using high-performance liquid chromatography–mass spectrometry (HPLC–MS), revealing a diverse phytochemical composition. Identified compounds were screened against the full-length crystal structure of Hsp90α using a structure-based computational workflow that included extra-precision and domain-specific molecular docking, molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Pharmacokinetic and toxicity profiles were evaluated through ADMET predictions. This study elucidated the chemical composition of the plant and identified two hit compounds: Forsythoside B bound preferentially to the middle domain, potentially interfering with client protein interactions, and chlorogenic acid targeted the C-terminal domain, which regulates dimerization and allosteric activity. Both ligands displayed stable protein–ligand interactions during MD and favorable ADMET properties. These findings provide the first integrated chemical and computational prediction framework, suggesting that some M. vulgare metabolites may interact with Hsp90, highlighting its potential as a source of novel anticancer scaffolds and laying the groundwork for experimental validation and drug development.

11 April 2025 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
MCMohammed Walid Chemao-Elfihri
Mohammed Walid Chemao-Elfihri
MHMohammed Hakmi
Mohammed Hakmi
HAHanane ABBOU
Hanane ABBOU
SKSouad Kartti
Souad Kartti
EFElmostafa El Fahime
Elmostafa El Fahime
SBSaber Boutayeb
Saber Boutayeb

8 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
IZIlham Zarguan
Ilham Zarguan
HAHanane ABBOU
Hanane ABBOU
RZRazana Zegrari
Razana Zegrari
RFRihab FESTALI
Rihab FESTALI
DBDevan Buchanan
Devan Buchanan
LBLamiae Belayachi Belayachi
Lamiae Belayachi Belayachi
Marrubium vulgare L. is a medicinal plant widely used in traditional medicine, with emerging evidence of anticancer potential. This study investigated its bioactive com-pounds as inhibitors of Heat Shock Protein 90 alpha (Hsp90α), a molecular chaperone essential for oncogenic protein stability. Organic and aqueous extracts were profiled using high-performance liquid chromatography–mass spectrometry (HPLC–MS), re-vealing a diverse phytochemical composition. Identified compounds were screened against the full-length crystal structure of Hsp90α using a structure-based computa-tional workflow that included extra-precision and domain-specific molecular docking, molecular dynamics (MD) simulations, and MM/GBSA binding free energy calculations. Pharmacokinetic and toxicity profiles were evaluated through ADMET predictions. This study elucidated the chemical composition of the plant and identified two hit com-pounds: Forsythoside B bound preferentially to the middle domain, potentially inter-fering with client protein interactions, and chlorogenic acid targeted the C-terminal domain, which regulates dimerization and allosteric activity. Both ligands displayed stable protein–ligand interactions during MD and favorable ADMET properties. These findings provide the first integrated chemical and computational analysis of M. vulgare targeting Hsp90α, highlighting its potential as a source of novel anticancer scaffolds and laying the groundwork for experimental validation and drug development.

30 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HAHanane ABBOU
Hanane ABBOU
RFRihab Festali
Rihab Festali
MCMohammed Walid Chemao-Elfihri
Mohammed Walid Chemao-Elfihri
MHMohammed Hakmi
Mohammed Hakmi
SKSouad Kartti
Souad Kartti
RERachid Eljaoudi
Rachid Eljaoudi
The Endocannabinoid System (ECS) is vital for human physiology, and genetic variation within its components can alter function and therapeutic responses. The genetically diverse Moroccan population offers a unique opportunity for pharmacogenomic insight. This study performs a comprehensive genomic analysis of 11 core ECS genes in 109 Moroccan individuals, identifying 170 novel variants. We then performed a deep in silico functional characterization of a novel, high-confidence CNR1 variant (V392A). Extensive, triplicate 500 ns molecular dynamics (MD) simulations were conducted on both the wild-type (WT) and mutant (MT) CB1 receptor. The simulations revealed that the V392A mutation induces significant structural destabilization, evidenced by increased RMSD/RMSF, a consistent loss of α-helicity, and altered interhelical distances crucial for G-protein coupling. Free Energy Landscape (FEL) analysis confirmed the mutant receptor occupies a broader, higher-energy conformational state. This “genomics-to-function” pipeline demonstrates that the Moroccan population harbors significant novel ECS genetic diversity and that the unique V392A CNR1 variant impairs CB1 receptor stability, suggesting a potential for altered signaling and pharmacological responses.

10 February 2026 in Journal of Cannabis Research
Verified
Journal Article
Open access
PDF file
HAHanane ABBOU
Hanane ABBOU
LBLahcen Belyamani
Lahcen Belyamani
RERachid Eljaoudi
Rachid Eljaoudi
Background: Minor cannabinoids, including cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC), are gaining scientific attention for their distinct therapeutic potential beyond THC and CBD. Despite this growing interest, research on these compounds remains fragmented and underrepresented in the literature. This study aims to map the global research landscape of minor cannabinoids through bibliometric mapping analyses, identifying key trends, collaboration patterns, and emerging thematic areas. Methods: A structured database search of the Scopus, PubMed, and WOS databases identified 1516 eligible articles published between 1969 and 2024. An inclusive search strategy was employed to capture minor cannabinoid research as it is embedded within the broader cannabinoid literature, ensuring that studies co-analyzing major and minor cannabinoids were not overlooked. Bibliometric analysis was conducted using the Biblioshiny tool to assess publication trends, journal impact, geographic distribution, and author collaboration networks. Results: Publication activity showed exponential growth starting in 2017, reaching a peak in 2024. The United States, Italy, and Canada led global contributions, with widespread international collaboration. Core publishing venues included Molecules, The Journal of Analytical Toxicology , the British Journal of Pharmacology , and Cannabis and Cannabinoid Research . Keyword co-occurrence analysis revealed three major thematic clusters. A sharp thematic shift has been observed since 2015, highlighting the rise of “ CBG”, “CBGA” and “molecular docking”. This evolution marks a convergence of traditional pharmacology with molecular targeting and bioinformatics, signaling a transition toward computational and receptor-targeted research. Conclusions: Minor cannabinoid research is expanding rapidly, with strong interdisciplinary foundations and growing global collaboration. This study provides a comprehensive overview of the field’s evolution and highlights underexplored areas ripe for future investigation.

12 June 2026 in Scientific Reports
Verified
Journal Article
Open access
HAHanane ABBOU
Hanane ABBOU
ZGZainab Gaouzi
Zainab Gaouzi
RZRazana Zegrari
Razana Zegrari
SKSouad Kartti
Souad Kartti
MHMohammed Hakmi
Mohammed Hakmi
RERachid ElJaoudi
Rachid ElJaoudi
Measles virus (MeV) remains a serious public health concern, necessitating the development of effective antivirals targeting the viral fusion (F) glycoprotein. This study employed a robust computational pipeline, including molecular docking, 1000 ns all-atom molecular dynamics (MD) simulations, and free energy landscape (FEL) analysis, to evaluate minor cannabinoids as novel inhibitors of the MeV F protein. Initial virtual screening identified Cannabichromenic acid (CBCA), Cannabichromevarin (CBCV), and Cannabiripsol (CBR) as high-affinity leads, with docking scores of - 8.5, - 8.2, and - 8.1 kcal/mol, respectively, outperforming the reference inhibitor AS-48 (- 7.6 kcal/mol). Post-MD binding free energy calculations (MM-GBSA) further confirmed the thermodynamic superiority of CBCV (ΔGbind = - 44.7 kcal/mol) and CBCA (ΔGbind = - 30.1 kcal/mol) over the reference. Dynamic analyses revealed that CBCV and CBCA effectively stabilize the F protein in its inactive prefusion conformation through a conformational locking mechanism. CBCV induced the most significant structural compaction (Rg = 2.4 nm) and displayed the sharpest global energy minimum (0.3 kcal/mol) in the FEL. Furthermore, ADMET profiling and ProTox-3.0 toxicity modeling identified CBCV as the most promising lead, possessing excellent drug-likeness, an inactive toxicity profile, and predicted blood-brain barrier permeability. This work establishes minor cannabinoids as novel scaffolds for anti-MeV drug development, positioning CBCV as a strong candidate for treating systemic and neurological complications of measles, such as Subacute Sclerosing Panencephalitis.